Unmet need is driving more R&D and treatment options for rheumatoid arthritis—but it won’t be easy for any newcomer to challenge the nine RA biologics that rule the space
With the FDA weighing a new Rx diet therapy, we review the anti-obesity sector. Noah Pines on the hype and hurdles for Vivus’s Qnexa and its would-be competitors, and the diabetes controversy
New cardiovascular treatments are gaining FDA approval as massive brands lose patent protection. Noah Pines on the potential of these new entrants to replace that lost revenue
Makena, KV Pharma’s drug for preventing preterm birth, has been no bundle of joy. In an exclusive interview, Noah Pines finds how the firm has navigated its difficulties and started to rebuild trust
Targeted therapies have opened doors to tumor control. As drugmakers aim for more focused patient groups, realistic expectations on pricing and revenue potential are proving elusive, finds Noah Pines